CG Oncology, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
From time to time, our Section 16 officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K) for the purchase or sale of our securities. During the three months ended September 30, 2025, except for Arthur Kuan's adoption of a 10b5-1 plan for the purchase of our securities, none of our officers or directors adopted, modified orterminated any such trading arrangements.
| Type of Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Position · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares to be Purchased · Expiration Date | |||||
| Arthur Kuan, Chairman and Chief Executive Officer | Adoption | September 15, 2025 | X | 690,420 | The earliest to occur of (i) September 15, 2026, and (ii) the date the aggregate number of shares of stock purchased under the plan is 690,420 shares. |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | |||||
| ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.